Dr. Bing Yuan is a seasoned business executive and entrepreneur with 20+ years of biopharma experience, made significant contributions to 14 approved global oncology brands during his career, including blockbusters such as Keytruda and Glivec.

In early 2021, he co-founded OnCusp Therapeutics, a clinical stage biotech company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. He successfully built the team, developed a portfolio of innovative assets, and raised a total of $139M in Seed and Series A financing rounds supported by world leading biotech investors.

Before co-founding OnCusp, he was Chief Strategy and Business Officer at CStone Pharmaceuticals, achieved 10+ deals with leading global companies such as Pfizer, Bayer, Blueprint, Agios and EQRx.  As a senior executive from the beginning, he helped to build CStone from startup to successful IPO in just three years and had managed over 10 different business functions.

Prior to joining CStone in 2016, he was Global Lead of Oncology BD&L at Merck (MSD) in New Jersey, led or contributed to 30+ licensing, M&A and Keytruda clinical collaboration deals. Before Merck, he held various global commercial positions with increasing responsibilities at Novartis Oncology, most recently as Executive Director and Head, Brand Life Cycle Strategy. He also played key roles in new product strategy, business development and global launch of a lung cancer drug. He used to be Global Oncology Marketing Lead at Eisai, managing the oncology portfolio.

Dr. Yuan holds a Ph.D. in Molecular Biology from Columbia University, an MBA from Cornell University and a BS in Biochemistry from Nanjing University. 

Dr. Andy Fu has over 18 years of experience in healthcare, finance, management consulting, and biotech.

Before co-founding OnCusp, Dr. Fu was Vice President of Business Development and Corporate Strategy at CStone Pharmaceuticals. As a member of the founding management team, Dr. Fu played a critical role in designing CStone’s corporate strategy and leading the business development function. He closed eight partnerships in three years, including in-licensing, out-licensing, and multi-spectrum/equity deals. Prior to CStone, he was at Monitor Deloitte China, where he specialized in Life Sciences strategy and M&A and helped to build the Healthcare M&A practice working with some of the largest Chinese healthcare companies. Prior to Monitor Deloitte, Dr. Fu was deputy CEO at Yanlord Financial Services based in Sydney, Australia, where he co-led multiple M&A deals. Prior to Yanlord, Dr. Fu practiced as a pharmacist at Walgreens Pharmacy.

Dr. Fu holds both a Bachelor of Pharmacy and Doctor of Pharmacy from the University of Connecticut, and an MBA from INSEAD.

Dr. Eric Slosberg has over 20 years of experience leading oncology drug research and development for global pharmaceutical companies. His expertise includes design of clinical development plans, execution of clinical trials, and strategic drug portfolio development.

Before co-founding OnCusp, Dr. Slosberg was Vice President and Head of Oncology Global Translational Development at Daiichi Sankyo, where he directed the clinical and translational strategy and execution for all early oncology assets. Prior to Daiichi Sankyo, Dr. Slosberg spent almost 20 years at Novartis with increasing responsibilities in preclinical research and early and late-stage clinical development. In addition, he oversaw the US medical affairs activities of all benign hematology and multiple myeloma assets, and he developed and co-led the influential Signature personalized medicine clinical trial program.

Dr. Slosberg holds an M.S., M.Phil., and a PhD from Columbia University, as well as a Bachelor of Science from Cornell University.

Dr. Wei Lu has over 19 years of industrial experience in drug discovery and early developments in oncology and immunology. Over his career, he brought 6 small molecules and antibody-drug conjugate from drug discovery to clinical trials. Dr. Lu is also experienced in recruiting, building up and leading research teams at multiple biotech and large pharma organizations.

Before joining OnCusp, Dr. Lu worked as Senior Director at Skyhawk Therapeutics and KSQ Therapeutics. Prior to that, he held various roles from Senior Research Biochemist to Director of Biology in Forma Therapeutics and Merck Research Laboratory in Boston. He led the mutant selective IDH1 program from target nomination to the entry of Ph1 study of FT-2102 (Olutasidenib), which was approved by FDA in 2022 for the treatment of mutant IDH1-harboring acute myeloid leukemia.

Dr. Lu completed his postdoctoral fellowship training at Harvard Medical School. He holds a Ph.D. in Biochemistry and Molecular Pharmacology from Johns Hopkins University, School of Medicine, an M.S. of Biochemistry from Bowling Green State University, and a B.S. of Polymer Science and Engineering, East China University of Chemical Technology.

Amy Penticoff brings 30+ years of product development, manufacturing, quality control, regulatory strategy and supply chain of small molecule and biologic drugs to OnCusp.

Most recently she was VP of Technical Operations at Amphivena Therapeutics, where she was responsible for a bispecific T-cell engager, as well as the development of a prefilled syringe. Before that, at ARMO BioSciences (now Eli Lilly), she was responsible for drug product manufacture in support of the company’s clinical trials as well as the development of a prefilled syringe. Following ARMO’s acquisition, Ms. Penticoff oversaw the transfer of the product manufacturing technology from ARMO to Eli Lilly. Prior to ARMO, at Intarcia Therapeutics, she worked on a peptide-based implantable product for the treatment of diabetes and the development of a sterile implantation kit intended for commercialization. Before that, at NeurogesX, Inc., she supported the development and commercialization of a small molecule dermal patch and topical products.

Ms. Penticoff holds a B.S. in Chemistry from the University of Illinois, Urbana-Champaign, and an MBA from Pepperdine University, and holds patents in formulation and manufacturing.

Priya Marreddy has more than 20 years of experience in Clinical Development and Operations spanning multiple therapeutic areas in large and mid-sized Pharmaceutical and Biotech companies as well as CROs and Startups.  

Before joining OnCusp, Ms. Marreddy was the Vice President of Clinical Operations at Context Therapeutics, where she focused on advancing both small molecule and bispecific antibody investigational therapies to treat female cancers from preclinical to clinical stage development. Prior to that, Ms. Marreddy served as Head of Clinical Operations at Rafael Pharmaceuticals (now Cornerstone Pharmaceuticals) where she built and led the Clinical Operations organization in planning and executing rare cancer clinical trials. Prior to that, Ms. Marreddy held various leadership roles at Spark Therapeutics, Jazz Pharmaceuticals, and Teva Pharmaceuticals where she managed and led multinational, cross-functional teams in strategy, design, and execution of global clinical development plans as well as the implementation of best clinical practices and quality improvement.

Ms. Marreddy earned her undergraduate degree from George Washington University and completed her Master’s Degree in Molecular Biology at the University of Pennsylvania.

Daphne Farrington has more than 25 years of drug development experience in biotechnology and pharmaceutical companies spanning from target identification to regulatory approval and launch. Her expertise includes biomarker assay development and application, clinical trial design and implementation, and clinical development strategy.

Before OnCusp, Ms. Farrington was Head of Clinical Science, Cellular Therapies at Editas Medicine where she was the Program Lead for renizgamglogene autogedtemcel (EDIT-301), autologous cell therapy for Sickle Cell Disease and Transfusion-Dependent Thalassemia, and responsible for the clinical strategy for the early oncology portfolio prior to the sale to Shoreline Biosciences in 2023. Prior to Editas Medicine, she was Head of Clinical Science at Verastem Oncology and played a pivotal role in the registration of COPIKTRA (duvelisib)  in the US and the EU. Prior to Veratem Oncology, Ms. Farrington spent almost 20 years at Eli Lilly and Company with increasing responsibilities in preclinical research, translational medicine, and ultimately leading several oncology early phase clinical research programs.

Ms. Farrington holds an Master of Science in Biochemistry and Molecular Biology and a Bachelor of Science in Biology from Indiana University.

Robert L. Phillips, Ph.D., is a scientist with a long background in biomarkers, patient selection, and development of drug-linked diagnostics, with a particular focus on Oncology.

He comes to us having recently served as VP and Head of Translational Sciences at Daiichi-Sankyo, in charge of CDx and Biomarkers for the entire pipeline. Prior to DS, he was Vice President and Head of Precision Medicine at Pfizer, and before that, Head of Precision Medicine for all therapeutic areas at Regeneron Pharmaceuticals, where he co-founded the Regeneron Genetics Center.

Earlier, Robert was the Deputy Head for the Oncology Biomarkers and Imaging group for Novartis Oncology. He spent nine years at Merck & Co. in New Jersey in positions of increasing responsibility, having led the Basic Research Molecular Profiling group and Merck's Oncology Biomarkers efforts. Robert received his doctorate in Cell Biology from the University of Michigan in Ann Arbor and finished a post-doctoral fellowship at Princeton University in Molecular Biology.

At home, Robert is an avid cook and splits time between Manhattan and his horse farm in New Jersey.

Dr. Hagop Youssoufian is a physician-scientist with more than 25 years of experience in drug development, which spans all aspects of product development including translational research, clinical development strategy and execution, translational research, and regulatory strategy.

Dr. Youssoufian has held faculty positions at Harvard Medical School and Baylor College of Medicine and leadership positions at ImClone/Lilly, Ziopharm, Progenics and BIND Therapeutics, as well as prior roles at Bristol-Myers Squibb and Sanofi Aventis. Altogether he has led or contributed to ten drug approvals, including Erbitux and Cyramza.

Dr. Youssoufian received a B.S. in biology from Boston College and a M.Sc. and M.D. from the University of Massachusetts Medical School, followed by clinical and research fellowships at Johns Hopkins, Harvard Medical School, and Whitehead Institute.

Dr. Bing Yuan is a seasoned business executive and entrepreneur with 20+ years of biopharma experience, made significant contributions to 14 approved global oncology brands during his career, including blockbusters such as Keytruda and Glivec.

In early 2021, he co-founded OnCusp Therapeutics, a clinical stage biotech company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. He successfully built the team, developed a portfolio of innovative assets, and raised a total of $139M in Seed and Series A financing rounds supported by world leading biotech investors.

Before co-founding OnCusp, he was Chief Strategy and Business Officer at CStone Pharmaceuticals, achieved 10+ deals with leading global companies such as Pfizer, Bayer, Blueprint, Agios and EQRx.  As a senior executive from the beginning, he helped to build CStone from startup to successful IPO in just three years and had managed over 10 different business functions.

Prior to joining CStone in 2016, he was Global Lead of Oncology BD&L at Merck (MSD) in New Jersey, led or contributed to 30+ licensing, M&A and Keytruda clinical collaboration deals. Before Merck, he held various global commercial positions with increasing responsibilities at Novartis Oncology, most recently as Executive Director and Head, Brand Life Cycle Strategy. He also played key roles in new product strategy, business development and global launch of a lung cancer drug. He used to be Global Oncology Marketing Lead at Eisai, managing the oncology portfolio.

Dr. Yuan holds a Ph.D. in Molecular Biology from Columbia University, an MBA from Cornell University and a BS in Biochemistry from Nanjing University. 

Chau Q. Khuong is a seasoned healthcare investor and entrepreneur with over two decades of experience investing in private and public biotechnology and medical device companies. He currently manages investments from CJNV BioVentures, a life sciences focused entity he founded in 2022 to provide capital solutions and strategic advisory to life science entrepreneurs. From 2003 to 2021 Mr. Khuong worked at OrbiMed Advisors, where he was Partner and member of the investment committee directing capital deployment from OrbiMed’s flagship venture capital funds. Mr. Khuong has served on the Board of Directors of numerous biotech companies such as Arius Research, Bellus Health, Glaukos Medical, Inspire Medsystems, Intellia, Rempex, and ReViral Ltd.

Mr. Khuong received a B.S. (Molecular Biology) and an MPH (Infectious Disease Epidemiology) from Yale University.

Chong Xu, Ph.D., is a Partner at F-Prime Capital, focusing on biopharmaceutical and medical technology sectors. He has been involved in a number of company formations including as a founding investor of Skyline Therapeutics, K36 Therapeutics, and RareStone Group. Prior to F-Prime, Dr. Xu was an associate at McKinsey, a healthcare equity analyst at Massif Partners and Affirmed Healthcare, and a researcher at Temasek Life Sciences Laboratory.

Dr. Xu holds a Ph.D. in cell biology from the University of Virginia, an MBA from the Darden School of Business at the University of Virginia, and a B.S. in biology from Zhejiang University.

Mr. Xu is a Principal on the Private Equity team and has been with OrbiMed since 2012. Prior to joining OrbiMed, Mr. Xu was an investment banking analyst in the healthcare group at Lazard where he focused on M&A, financing, and strategic advisory for biotech, diagnostics, and pharma clients in the U.S., Japan, and E.U.

Mr. Xu holds M.S. degrees in management science/engineering from Stanford and a M.S. in molecular/cellular biology from Dartmouth, as well as a B.S. in biology from Zhejiang University.

Dr. Enoch Kariuki is President of Endeavor BioMedicines. He is an accomplished life sciences executive with extensive strategic, operational, and financial experience. He previously served as the Chief Executive Officer of Lengo Therapeutics (acquired by Blueprint Medicines) and was the Chief Financial Officer of VelosBio (acquired by Merck). Prior to that, Dr. Kariuki was Senior Vice President, Corporate Development at Synthorx (acquired by Sanofi). He also previously served as Board Director and Audit Chair of Imago Biosciences (acquired by Merck) and ProfoundBio (acquired by Genmab). He is currently a Board Director and Audit Chair of Zentalis (NASDAQ: ZNTL).

Before Synthorx, Dr. Kariuki was Vice President at H.I.G. Capital (a $60 billion+ private equity fund), where he led investments into, and served on the boards of, several life sciences companies. His other previous roles include Senior Associate at Leerink Partners and Associate Director at UBS Investment Bank. At Leerink and UBS, Dr. Kariuki advised healthcare companies on equity capital financings, mergers, and acquisitions, leveraged buyouts, and recapitalizations.

Dr. Kariuki completed a Post-Doctoral Fellowship in R&D Strategy and Analytics at Bristol-Myers Squibb and was a Pharmacist at CVS Caremark. He holds an MBA from the Tuck School of Business at Dartmouth College and a PharmD from Texas Southern University.

Jiacong Guo, Ph.D. is a Principal at BioTrack Capital. Prior to BioTrack, he was an Assistant Director at the CEO Office at WuXi Biologics. Dr. Guo currently serves on the Boards of Directors for OnCusp Therapeutics, Innogen, and Shanton Pharma. He has also worked at Hillhouse Capital Management and Bristol Myers Squibb. Dr. Guo began his career as a Research Assistant at the University of Southern California.

Dr. Guo holds a Ph.D. and B.S. in Oncology and Cancer Immunotherapy from the University of Southern California.

Raymond Camahort, Ph.D., is a Partner at Novo Holdings Venture Investments. He has over 15 years of investment, business, and research experience, with expertise in biochemistry, genetics, and gene therapy/editing. Prior to Novo, he worked in business development at Harvard University Office of Technology Development. Dr. Camahort has served on the boards of several companies Arcellx, Inspirna, iECURE, Riva Therapeutics, and OnCusp Therapeutics.

Dr. Camahort holds a Ph.D. in biochemistry and molecular biology from the University of Kansas and a B.S. from the University of California Santa Barbara. He also completed postdoctoral training at Harvard and a pre-doctoral fellowship at the Stowers Institute.

Mr. Forrester has 30 years of life sciences experience and has held leadership roles in private and public biotech companies. He is a co-founder of IDRx, Sesame Therapeutics, EQRx, Brixton Biosciences, EyeCool Therapeutics, Sevenoaks Biosystems and Momelan Technologies. He has served as the CXO of EQRx, CEO of Verastem Oncology, COO of Forma Therapeutics, CEO of CombinatoRx, and CFO of Coley Pharmaceutical. He also serves on the boards of Anagenex, Deciduous Therapeutics, OnCusp Therapeutics, and Peel Therapeutics. Mr. Forrester served as Managing Director of the Proprietary Investment Group at MeesPierson. Prior to MeesPierson, Mr. Forrester worked for the investment banks, Barclays Capital and UBS, in the corporate finance groups undertaking M&A, and public and private finance transactions. Mr. Forrester started his career as a lawyer with Clifford Chance in London, Singapore and Brunei.

Mr. Forrester holds an LL.B. from Bristol University, UK.